Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-10-50 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma

Roque Joao , Silva Tiago , Leite Valeriano

Introduction and objectives: Poorly differentiated thyroid carcinoma (PDTC) is a rare but aggressive thyroid tumor. PDTC frequently presents in advanced stages and conventional treatments are usually less effective than in differentiated thyroid carcinoma (DTC). Lenvatinib is a multi-kinase inhibitor approved for the treatment of radioiodine-refractory DTC, with significant improvement in progression free survival. Despite the inclusion of a minority PDTC patients in SELECT tr...

ea0081ep575 | Endocrine-Related Cancer | ECE2022

Somatostatin analogues in the treatment of metastatic paraganglioma

Roque Joao , Regala Catarina , Silva Tiago , Leite Valeriano

Introduction: Paraganglioma (PGL) is a neuroendocrine tumor derived from extra adrenal autonomic paraganglia with a germinal mutation rate of 30%. Metastatic paraganglioma (MPGL) can only be predicted after evidence of secondary lesions and it can occur in up to 50% of cases. Clinical course is remarkably variable, but 5-year overall survival is generally around 50%. Treatment options include surgical resection, chemotherapy, radiotherapy, and 123I-MIBG. Being a neu...

ea0067gp1 | Poster Presentations | EYES2019

Papillary thyroid carcinoma and Graves disease: a case report

Pinheiro Sara Lomelino , Silva Tiago , Pereira Conceicao , Leite Valeriano

Background: Papillary thyroid cancer (PTC) is the most common type of thyroid carcinoma, but it rarely presents as an intrathoracic mass with concurrent hyperthyroidism due to Graves disease.Case presentation: A 73-year-old man presented with weight loss. Imaging by computed tomography (CT) documented a large mediastinal mass in the infrathyroidal space separate from the thyroid gland and pulmonary lesions suggestive of metastases. Neck ultrasound showed...

ea0070ep35 | Adrenal and Cardiovascular Endocrinology | ECE2020

Mediastinal malgnant paraganglioma: An atypical presentation

Pinheiro Sara , Damasio Ines , Nunes da Silva Tiago , Leite Valeriano

Introduction: Mediastinal paragangliomas are rare. These tumours can be associated with increased morbidity and mortality when invasive growth to the heart, great vessels, esophagus and trachea occurs. Surgical resection, if feasible, is the treatment of choice.Case report: A 50-year-old man presented with severe and refractory left gluteal pain radiating to the posterior thigh for two months. The patient had no relevant medical history and no other symp...

ea0055wa13 | Workshop A: Disorders of the hypothalamus and pituitary (I) | SFEEU2018

Cushing’s disease relapse associated with central diabetes insipidus

Ferreira Ana , Silva Tiago , Bastos Filipa , Manita Isabel , Cordeiro Maria Carlos , Portugal Jorge

Introduction: Central diabetes insipidus (DI) is a frequent complication of transfenoidal surgery for Cushing’s disease (CD). It can be transient or, more infrequently, permanent. The most common mechanism results from surgical neurohypophyseal damage rather than local mass effect from the pituitary adenoma.Case report: A 40 years old woman was referred to our Endocrinology outpatient clinic at the beginning of 2015 for new onset hypertension, signi...

ea0084ps1-03-27 | Thyroid Cancer CLINICAL 1 | ETA2022

Clinical significance and prognosis of solid / trabecular component areas of papillary thyroid carcinoma

Pinheiro Sara , Damasio Ines , Simoes-Pereira Joana , Nunes da Silva Tiago , Leite Valeriano

Introduction: the presence of areas with a solid / trabecular growth pattern in differentiated papillary thyroid carcinoma (PTC) represents a source of controversy regarding clinical and prognostic significance and usually requires a more aggressive therapeutic approach. The aim of this study was to compare clinicopathological characteristics, treatments and prognosis of PTC with and without solid component (SC). We also aimed to evaluate whether SC affects patient outcome in ...

ea0049ep226 | Bone & Osteoporosis | ECE2017

Cinacalcet for control of primary hyperparathyroidism: a single centre experience

da Silva Tiago Nunes , Ferreira Ana Goncalves , Cordeiro Maria Carlos , Matos Ana Catarina , Portugal Jorge

Although primary hyperparathyroidism (PHPT) is usually cured by surgery, some individuals are unable to undergo parathyroidectomy and are refractory to standard calcium lowering medical therapy. In such cases, targeted therapy with cinacalcet may be useful.The aim of this study was to access the short-term efficacy of cinacalcet in lowering calcium (Ca2+) levels in patients with PHPT unable to undergo parathyroidectomy and refractory to standa...

ea0075a08 | Adrenal gland | EYES2021

Ectopic cushing’s syndrome secondary to acinic cell carcinoma of the parotida gland: A case-report

Pinheiro Sara , Filipe Juliana , Meireles Pedro , Castelo Branco Sara , Rito Miguel , Nunes da Silva Tiago

Background: Ectopic ACTH secretion from metastatic acinic cell carcinoma (ACC) of the parotid gland is extremely rare. ACC is an uncommon, typically indolent, salivary gland neoplasm. Herein, we report a case of a high-grade ACC later diagnosed with Cushing’s syndrome (CS).Case presentation: A 60-year-old man presented with a laterocervical mass. Computed tomography (CT) documented a 39×38 mm mass on the parotid gland and homolateral cervical l...

ea0092ps3-29-04 | Treatment 2 | ETA2023

Effectiveness of lenvatinib in progressive metastatic radioiodine refractory well differentiated and poorly differentiated thyroid carcinoma

Nunes da Silva Tiago , Regala Catarina , Rodrigues Ricardo , Roque Joao , Damasio Ines , Cavaco Branca , Leite Valeriano

Introduction and objectives: Lenvatinib is the first line treatment for advanced radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC). Poorly differentiated thyroid carcinoma (PDTC) outcomes with Lenvatinib have only been subjected to sub analysis in one PHASE III study (SELECT), which might limit its real-world use in PDTC. We intend to compare the effectiveness of Lenvatinib in metastatic RAIR DTC and PDTC patients.Methods: Retrospectiv...

ea0084op-03-16 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

A clinical and molecular study of a real-world cohort of braf v600e anaplastic thyroid carcinoma treated with dabrafenib and trametinib

Nunes da Silva Tiago , Rodrigues Ricardo , Rito Miguel , Saramago Ana , Pires Carolina , Horta Mariana , Leite Valeriano , Cavaco Branca

Introduction and objectives: Anaplastic thyroid cancer (ATC) has a very low overall survival (OS) and progression free survival (PFS) due to fast growth and resistance to non-target therapies. A recent phase II study showed a dramatic increase in OS and PFS of BRAF V600E mutated ATC patients treated with Dabrafenib and Trametinib (DT). However as commonly reported in melanoma durable responses in ATC may be compromised by resistance mechanisms. Until now only a few ca...